A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).

The present invention provides a Lactobacillus fermentum GKF3, a composition comprising the strain and their use, in which the aforementioned Lactobacillus fermentum GKF3, deposited with accession numbers of BCRC 910824 and CGMCC 15203, can increase the levels of dopamine or/and serotonin in brain tissues, thereby improving the symptoms of the psychataxia such as decreased focus.

The present invention provides a Lactobacillus fermentum GKF3, a composition comprising the strain and their use, in which the aforementioned Lactobacillus fermentum GKF3, deposited with accession numbers of BCRC 910824 and CGMCC 15203, can increase the levels of dopamine or/and serotonin in brain tissues, thereby improving the symptoms of the psychataxia such as decreased focus.

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.

The present invention relates to human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 and to a pharmaceutical composition for the prevention or treatment of obesity-related diseases, containing the same as an active ingredient, and a food composition, quasi-drug composition and functional health food. The Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits anti-obesity activity that inhibits lipase enzyme activity, preadipocyte differentiation and neutral lipid accumulation, has high autoaggregation ability to thus show excellent colony formation ability on the epithelial cells of the digestive tract, and is resistant to acid and bile. Thereby, the Lactobacillus fermentum MG4231 strain or the MG4244 strain can be variously utilized in a pharmaceutical composition for the prevention and treatment of obesity-related diseases, and a food composition, quasi-drug composition and functional health food.

Disclosed herein are a starter culture and a fermented product prepared using such starter culture. The starter culture comprises a mixture of Lactobacillus fermentum strain LF26, Lactobacillus helveticus strain LH43, Lactobacillus paracasei strain LPC12, Lactobacillus rhamnosus strain LRH10, and Streptococcus thermophilus strain ST30. Also disclosed herein are methods for reducing fatigue, improving exercise performance, and/or modifying gut microbiota. Each of these methods includes administering to a subject the fermented product.

Disclosed herein are a starter culture and a fermented product prepared using such starter culture. The starter culture comprises a mixture of Lactobacillus fermentum strain LF26, Lactobacillus helveticus strain LH43, Lactobacillus paracasei strain LPC12, Lactobacillus rhamnosus strain LRH10, and Streptococcus thermophilus strain ST30. Also disclosed herein are methods for reducing fatigue, improving exercise performance, and/or modifying gut microbiota. Each of these methods includes administering to a subject the fermented product.

The present invention relates to a method for processing coffee cherries using deep seawater and microorganisms. The method processes coffee cherries by using microorganisms and deep seawater, such that the amount of defective coffee cherries are reduced, a processing time of green beans is shortened, and a content of trigonelline which is a precursor of an aroma component of coffee is increased.

The present invention relates to a prebiotic composition comprising a microbially produced oligosaccharide, wherein the oligosaccharide is characterized by being selective for a pre-determined probiotic bacterial strain and also capable of being produced by the pre-determined probiotic bacteria by reverse enzyme action. The present invention also relates to methods of screening a composition suitable for use as a prebiotic and methods for screening of prebiotics for incorporation into synbiotic formulations.

The present invention relates to a prebiotic composition comprising a microbially produced oligosaccharide, wherein the oligosaccharide is characterized by being selective for a pre-determined probiotic bacterial strain and also capable of being produced by the pre-determined probiotic bacteria by reverse enzyme action. The present invention also relates to methods of screening a composition suitable for use as a prebiotic and methods for screening of prebiotics for incorporation into synbiotic formulations.